Intra-cellular Therapies, Inc. (ITCI)

$73.54

+1.12

(+1.55%)

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $73.05
    $76.11
    $73.54
    downward going graph

    0.67%

    Downside

    Day's Volatility :4.02%

    Upside

    3.38%

    downward going graph
  • $45.50
    $84.89
    $73.54
    downward going graph

    38.13%

    Downside

    52 Weeks Volatility :46.4%

    Upside

    13.37%

    downward going graph

Returns

PeriodIntra-cellular Therapies, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
7.5%
5.1%
0.0%
6 Months
10.22%
4.9%
0.0%
1 Year
27.76%
16.6%
0.0%
3 Years
116.36%
13.2%
-22.3%

Highlights

Market Capitalization
7.8B
Book Value
$10.84
Earnings Per Share (EPS)
-0.87
PEG Ratio
0.0
Wall Street Target Price
95.84
Profit Margin
-14.93%
Operating Margin TTM
-17.18%
Return On Assets TTM
-6.91%
Return On Equity TTM
-9.63%
Revenue TTM
564.5M
Revenue Per Share TTM
5.75
Quarterly Revenue Growth YOY
45.7%
Gross Profit TTM
95.2M
EBITDA
-112.0M
Diluted Eps TTM
-0.87
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.67
EPS Estimate Next Year
0.72
EPS Estimate Current Quarter
-0.19
EPS Estimate Next Quarter
-0.14

Analyst Recommendation

Buy
    86%Buy
    13%Hold
    0
    0%Sell
Based on 23 Wall street analysts offering stock ratings for Intra-cellular Therapies, Inc.(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
19
20
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 30.32%

Current $73.54
Target $95.84

Technicals Summary

Sell

Neutral

Buy

Intra-cellular Therapies, Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Intra-cellular Therapies, Inc.
Intra-cellular Therapies, Inc.
-0.12%
10.22%
27.76%
116.36%
611.91%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-16.62%
-11.2%
10.78%
28.21%
20.17%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
7.49%
20.82%
28.48%
39.41%
39.41%
Zoetis Inc.
Zoetis Inc.
2.41%
4.25%
0.77%
-8.94%
49.4%
Viatris Inc.
Viatris Inc.
-0.79%
-8.6%
12.7%
-23.12%
-31.03%
Catalent, Inc.
Catalent, Inc.
0.82%
6.48%
22.57%
-57.47%
16.16%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Intra-cellular Therapies, Inc.
Intra-cellular Therapies, Inc.
NA
NA
0.0
-0.67
-0.1
-0.07
NA
10.84
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
36.53
36.53
0.27
4.57
0.16
0.12
NA
24.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
33.32
33.32
1.47
0.39
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
36.6
36.6
2.61
5.82
0.49
0.14
0.01
10.94
Viatris Inc.
Viatris Inc.
224.4
NA
0.07
2.68
-0.03
0.03
0.04
16.36
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.87
0.2
-0.25
0.0
NA
19.91
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Intra-cellular Therapies, Inc.
Intra-cellular Therapies, Inc.
Buy
$7.8B
611.91%
NA
-14.93%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$12.2B
20.17%
36.53
16.0%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$47.1B
39.41%
33.32
9.66%
Zoetis Inc.
Zoetis Inc.
Buy
$85.7B
49.4%
36.6
26.29%
Viatris Inc.
Viatris Inc.
Hold
$13.5B
-31.03%
224.4
-4.24%
Catalent, Inc.
Catalent, Inc.
Hold
$10.9B
16.16%
211.02
-23.81%

Insights on Intra-cellular Therapies, Inc.

  • Increasing Revenue

    Revenue is up for the last 18 quarters, 882.51K → 161.38M (in $), with an average increase of 23.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -15.24M → -16.21M (in $), with an average decrease of 6.4% per quarter

  • Vs HLN

    In the last 1 year, Haleon Plc Spon Ads has given 28.5% return, outperforming this stock by 0.7%

Institutional Holdings

  • FMR Inc

    10.60%
  • Vanguard Group Inc

    9.10%
  • BlackRock Inc

    5.99%
  • Wasatch Advisors LP

    3.52%
  • venBio Select Advisor LLC

    2.84%
  • Bellevue Group AG

    2.34%

Corporate Announcements

  • Intra-cellular Therapies, Inc. Earnings

    Intra-cellular Therapies, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.

Organization
Intra-cellular Therapies, Inc.
Employees
610
CEO
Dr. Sharon Mates Ph.D.
Industry
Health Technology

FAQs